Ngaosuwan Kanchana, Johnston Desmond G, Godsland Ian F, Cox Jeremy, Majeed Azeem, Quint Jennifer K, Oliver Nick, Robinson Stephen
Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College, London, UK.
Faculty of Medicine and Public Health, HRH Princess Chulabhorn College of Medical Science, Chulabhorn Royal Academy, Bangkok, Thailand.
J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2759-e2768. doi: 10.1210/clinem/dgab096.
Mortality data in patients with adrenal insufficiency are inconsistent, possibly due to temporal and geographical differences between patients and their reference populations.
To compare mortality risk and causes of death in adrenal insufficiency with an individually matched reference population.
A retrospective cohort study was done using a UK general practitioner database (CPRD). A total of 6821 patients with adrenal insufficiency (primary, 2052; secondary, 3948) were compared with 67564 individually-matched controls (primary, 20366; secondary, 39134). Main outcomes were all-cause and cause-specific mortality, and hospital admission from adrenal crisis.
With follow-up of 40 799 and 406 899 person-years for patients and controls respectively, the hazard ratio (HR [95% CI]) for all-cause mortality was 1.68 [1.58-1.77]. HRs were greater in primary (1.83 [1.66-2.02]) than in secondary (1.52 [1.40-1.64]) disease; primary versus secondary disease (1.16 [1.03-1.30]). The leading cause of death was cardiovascular disease (HR 1.54 [1.32-1.80]), along with malignant neoplasms and respiratory disease. Deaths from infection were also relatively high (HR 4.00 [2.15-7.46]). Adrenal crisis contributed to 10% of all deaths. In the first 2 years following diagnosis, the patients' mortality rate and hospitalization from adrenal crisis were higher than in later years.
Mortality was increased in adrenal insufficiency, especially primary, even with individual matching and was observed early in the disease course. Cardiovascular disease was the major cause but mortality from infection was also high. Adrenal crisis was a common contributor. Early education for prompt treatment of infections and avoidance of adrenal crisis hold potential to reduce mortality.
肾上腺皮质功能减退患者的死亡率数据并不一致,这可能是由于患者与其对照人群之间存在时间和地域差异。
比较肾上腺皮质功能减退患者与个体匹配的对照人群的死亡风险和死因。
使用英国全科医生数据库(CPRD)进行了一项回顾性队列研究。总共6821例肾上腺皮质功能减退患者(原发性,2052例;继发性,3948例)与67564例个体匹配的对照(原发性,20366例;继发性,39134例)进行了比较。主要结局为全因死亡率和死因特异性死亡率,以及肾上腺危象导致的住院情况。
患者和对照的随访时间分别为40799和406899人年,全因死亡率的风险比(HR[95%CI])为1.68[1.58 - 1.77]。原发性疾病(1.83[1.66 - 2.02])的HR高于继发性疾病(1.52[1.40 - 1.64]);原发性与继发性疾病相比(1.16[1.03 - 1.30])。主要死因是心血管疾病(HR 1.54[1.32 - 1.80]),以及恶性肿瘤和呼吸系统疾病。感染导致的死亡也相对较高(HR 4.00[2.15 - 7.46])。肾上腺危象占所有死亡的10%。在诊断后的前2年,患者的死亡率和肾上腺危象导致的住院率高于后期。
即使进行个体匹配,肾上腺皮质功能减退患者的死亡率仍会增加,尤其是原发性患者,且在疾病过程早期即可观察到。心血管疾病是主要死因,但感染导致的死亡率也很高。肾上腺危象是常见的死因之一。早期开展关于及时治疗感染和避免肾上腺危象的教育可能有助于降低死亡率。